Publication date: May 09, 2024
Current antigen delivery platforms, such as alum and nanoparticles, are not readily tunable, thus may not generate optimal adaptive immune responses. We created an antigen delivery platform by loading lyophilized Microporous Annealed Particle (MAP) with aqueous solution containing target antigens. Upon administration of antigen loaded MAP (VaxMAP), the biomaterial reconstitution forms an instant antigen-loaded porous scaffold area with a sustained release profile to maximize humoral immunity. VaxMAP induced CD4 T follicular helper (Tfh) cells and germinal center (GC) B cell responses in the lymph nodes similar to Alum. VaxMAP loaded with SARS-CoV-2 spike protein improved the magnitude, neutralization, and duration of anti-receptor binding domain antibodies compared to Alum vaccinated mice. A single injection of Influenza specific HA1-loaded-VaxMAP enhanced neutralizing antibodies and elicited greater protection against influenza virus challenge than HA1-loaded-Alum. Thus, VaxMAP is a platform that can be used to promote adaptive immune cell responses to generate more robust neutralizing antibodies, and better protection upon pathogen challenge.
| Concepts | Keywords |
|---|---|
| Biomaterial | Antigen delivery platform |
| Long | Biomaterial |
| Mice | Sustained release |
| Vaccine | Vaccine platform |
| Viral |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | VO | vaccine |
| disease | MESH | viral infection |
| pathway | REACTOME | Release |
| disease | IDO | cell |
| disease | VO | vaccinated |
| disease | VO | injection |
| disease | MESH | Influenza |
| drug | DRUGBANK | Tropicamide |
| disease | VO | pathogen challenge |